株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

膵外分泌機能不全:パイプライン分析

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 293887
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.79円で換算しております。
Back to Top
膵外分泌機能不全:パイプライン分析 Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2016
出版日: 2016年12月07日 ページ情報: 英文 47 Pages
概要

膵外分泌機能不全(EPI)は膵外分泌酵素の欠乏を特徴とする疾患で、消化不良を引き起こします。下痢、軟便、脂肪分が吸収されない脂肪便、ビタミン欠乏、食欲不振、原因不明の体重減少といった症状があります。治療には、膵酵素補充療法(PERT)、生活習慣の改善などがあります。

当レポートでは、世界における膵外分泌機能不全治療薬のパイプライン製品について取り上げ、現在の開発パイプラインの状況や最新動向、後期段階および中止されたプロジェクトの情報、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

膵外分泌機能不全の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

膵外分泌機能不全:開発中の治療薬:企業別

膵外分泌機能不全:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

膵外分泌機能不全:開発中の製品:企業別

膵外分泌機能不全:治療薬開発に従事している企業

  • Allergan Plc
  • Anthera Pharmaceuticals, Inc.
  • Cilian AG
  • Laboratoires Mayoly Spindler S.A.S.
  • Nordmark Arzneimittel GmbH & Co. KG

膵外分泌機能不全:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • burlulipase
  • Cilase
  • リプロタマーゼ
  • MS-1819
  • パンクレリパーゼDR
    • 製品概要
    • 作用機序
    • R&Dの進捗

膵外分泌機能不全:最近のパイプライン動向

膵外分泌機能不全:休止中のプロジェクト

膵外分泌機能不全:中止プロジェクト

膵外分泌機能不全:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8779IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2016, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape.

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat (steatorrhea), vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 1 respectively.Exocrine Pancreatic Insufficiency.

Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Exocrine Pancreatic Insufficiency Overview
  • Therapeutics Development
    • Pipeline Products for Exocrine Pancreatic Insufficiency - Overview
  • Exocrine Pancreatic Insufficiency - Therapeutics under Development by Companies
  • Exocrine Pancreatic Insufficiency - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Exocrine Pancreatic Insufficiency - Products under Development by Companies
  • Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
    • Adare Pharmaceuticals Inc
    • Anthera Pharmaceuticals Inc
    • Cilian AG
    • Laboratoires Mayoly Spindler SAS
    • Nordmark Arzneimittel GmbH & Co KG
  • Exocrine Pancreatic Insufficiency - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • burlulipase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cilase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • liprotamase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MS-1819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pancrelipase DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Exocrine Pancreatic Insufficiency - Dormant Projects
  • Exocrine Pancreatic Insufficiency - Discontinued Products
  • Exocrine Pancreatic Insufficiency - Product Development Milestones
    • Featured News & Press Releases
      • Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
      • Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura
      • Apr 29, 2016: Allergan Receives CHMP Positive Opinion For ENZEPI (Pancrelipase) For Patients With Exocrine Pancreatic Insufficiency (EPI)
      • Mar 19, 2015: Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
      • Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
      • Dec 10, 2012: Aptalis Pharma Announces US Commercial Availability Of Ultresa Delayed-release Capsules
      • Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
      • Mar 01, 2012: Aptalis Pharma Receives FDA Approval For ULTRESA Pancrelipase Delayed Release Capsules
      • Jul 14, 2011: Aptalis Pharma Receives FDA Approval Of 25,000 Lipase-Unit Strength Of ZENPEP
      • Jun 17, 2011: Aptalis Pharma Receives FDA Approval For New Low Strength Of ZENPEP
      • Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
      • Feb 11, 2011: Axcan Completes Acquisition of Eurand and Commences Subsequent Offering Period
      • Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
      • Jan 12, 2011: Eurand Announces Agreement With Nycomed for ZENPEP in Russia-CIS
      • Oct 21, 2010: Eurand Presents Data On ZENPEP Without Proton Pump Inhibitors Or H2 Receptor Antagonists For Treatment Of Pancreatic Insufficiency
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Exocrine Pancreatic Insufficiency - Pipeline by Adare Pharmaceuticals Inc, H2 2016
  • Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H2 2016
  • Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H2 2016
  • Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H2 2016
  • Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Exocrine Pancreatic Insufficiency - Dormant Projects, H2 2016
  • Exocrine Pancreatic Insufficiency - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top